Clinical Research Directory
Browse clinical research sites, groups, and studies.
Targeting Drug Memories With Methylphenidate
Sponsor: Icahn School of Medicine at Mount Sinai
Summary
This study aims to identify the neural, behavioral, and pharmacological mechanisms promoting diminished expression of drug-related memories in human drug addiction. In this fMRI study with a within-subjects placebo-controlled double-blind cross-over design, oral methylphenidate (20 mg) or placebo will be administered to individuals with cocaine use disorders (CUD) to peak during the retrieval of a drug-cue memory before extinction; in addition to fMRI activations, skin conductance responses (SCR, acquired simultaneously) will serve as the psychophysiological indicators of memory modification. Assessments of interference with the return of drug-cue memories via SCR and craving will be conducted the day following MRI. This pharmocologically-enhanced behavioral approach to decreasing drug memories and craving in iCUD could ultimately be used to develop effective cue-exposure therapies for drug addiction. Procedures include MRI, blood draw, questionnaires and interviews, skin conductance response measures, and behavioral tasks.
Official title: Targeting Neural, Behavioral and Pharmacological Mechanisms of Drug Memories in Drug Addiction With Methylphenidate
Key Details
Gender
All
Age Range
26 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
51
Start Date
2023-07-05
Completion Date
2026-09-03
Last Updated
2025-09-11
Healthy Volunteers
No
Interventions
Methylphenidate
Oral administration of 20 mg Methylphenidate
Memory reconsolidation
Retrieval of drug-cue memories before extinction.
Placebo
Matching placebo pill
Locations (1)
Icahn School of Medicine at Mount Sinai
New York, New York, United States